Zolpidemtartraat Sandoz 10,filmomhulde tabletten 10 mg

国: オランダ

言語: オランダ語

ソース: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

即購入

ダウンロード 製品の特徴 (SPC)
02-08-2023

有効成分:

ZOLPIDEMTARTRAAT

から入手可能:

Sandoz B.V. Veluwezoom 22 1327 AH ALMERE

ATCコード:

N05CF02

INN(国際名):

ZOLPIDEMTARTRAAT

医薬品形態:

Filmomhulde tablet

構図:

CELLULOSE, MICROKRISTALLIJN (E 460) ; HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMZETMEELGLYCOLAAT ; POLYETHYLEENGLYCOL (E 1521) ; TITAANDIOXIDE (E 171), CELLULOSE, MICROKRISTALLIJN (E 460) ; HYPROMELLOSE (E 464) ; LACTOSE 1-WATER ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMZETMEELGLYCOLAAT (E468) ; POLYETHYLEENGLYCOL (E 1521) ; TITAANDIOXIDE (E 171),

投与経路:

Oraal gebruik

治療領域:

Zolpidem

製品概要:

Hulpstoffen: CELLULOSE, MICROKRISTALLIJN (E 460); HYPROMELLOSE (E 464); LACTOSE 1-WATER; MAGNESIUMSTEARAAT (E 470b); NATRIUMZETMEELGLYCOLAAT (E468); POLYETHYLEENGLYCOL (E 1521); TITAANDIOXIDE (E 171);

承認日:

2001-03-13

情報リーフレット

                                Sandoz B.V.
Page 1/10
Zolpidemtartraat Sandoz 10, filmomhulde tabletten 10 mg
RVG 25109
1313-v15
1.3.1.3 Package Leaflet
Maart 2022
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ZOLPIDEMTARTRAAT SANDOZ® 10, FILMOMHULDE TABLETTEN 10 MG
zolpidem tartrate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What [nationally completed name] is and what it is used for
2.
What you need to know before you take [nationally completed name]
3.
How to take [nationally completed name]
4.
Possible side effects
5.
How to store [nationally completed name]
6.
Contents of the pack and other information
1.
WHAT
[NATIONALLY COMPLETED NAME] IS AND WHAT IT IS USED FOR
[Nationally completed name] is used for the short-term treatment of
insomnia in adults.
Do not use it long-term treatment. The duration of treatment should be
as short as possible because the
risk of dependence increases with increasing treatment duration.
It is used only when the sleep disorders are severe, disabling or
causing extreme distress for the
patient.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE [NATIONALLY COMPLETED NAME]
DO NOT TAKE [NATIONALLY COMPLETED NAME]
•
if you are
ALLERGIC
to zolpidem or any of the other ingredients of this medicine (listed
in section 6)
•
if you suffer from certain forms of
PATHOLOGIC MUSCLE WEAKNESS
(myasthenia gravis)
•
in case of
SHORT-TERM RESPIRATORY ARREST
while you are sleeping (sleep apnoea syndrome)
•
if you suffer from
ACUTE AND/OR SEVERE BREATHING WEAKNESS
(respiratory impairment)
•
if you suffer from
SEVE
                                
                                完全なドキュメントを読む
                                
                            

製品の特徴

                                Sandoz B.V.
Page 1/12
Zolpidemtartraat Sandoz
®
10, filmomhulde tabletten 10 mg
RVG 25109
1311-v16
1.3.1.1 Summary of Product Characteristics
Maart 2022
SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Zolpidemtartraat Sandoz 10, filmomhulde tabletten 10 mg
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 10 mg of zolpidem tartrate.
Excipients with known effect:
Each film-coated tablet contains 85.9 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Film-coated tablets.
White, oval, biconvex, film-coated tablets, scored on both sides and
embossed with "ZIM 10" on one
side
_. _
The score line is not intended for breaking the tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Zolpidem is indicated for short-term treatment of insomnia in adults.
Treatment is indicated only
when the disorder is severe, disabling or subjecting the individual to
extreme distress.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The duration of treatment should be as short as possible. It should
not exceed 4 weeks, including the
gradual discontinuation phase.
In certain cases treatment beyond this period may be necessary; if so,
it should not take place without
re-evaluation of the patient's condition, as the risk of abuse and
dependency increases with the
duration of the treatment (see section 4.4).
Posology
_Adults _
The treatment should be taken in a single intake and not be
re-administered during the same night.
The recommended daily dose for adults
is 10 mg to be taken immediately at bedtime. The lowest
effective daily dose of zolpidem should be used and
must not exceed 10 mg.
_Elderly and debilitated patients _
In elderly and debilitated patients who may be especially sensitive to
the effects of zolpidem a daily
dose of ½ film-coated tablet (corresponding to 5 mg zolpidem
tartrate) is recommended. This dose
Sandoz B.V.
Page 2/12
Zolpidemtartraat Sandoz
®
10, filmomhulde tabletten 10 mg
RVG 25109
1311-v16
1.3.1.1 Summary of Product 
                                
                                完全なドキュメントを読む